Endoscopic Ultrasound (EUS)-Guided Celiac Plexus Neurolysis (CPN) in the Management of Pain in Abdominal Non-pancreatic Malignancies
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pain
- Sponsor
- Northwestern University
- Locations
- 1
- Primary Endpoint
- Difference between the mean pain score prior to and 1 month after the procedure, as determined by the Brief Pain Inventory (BPI)
- Status
- Withdrawn
- Last Updated
- 11 years ago
Overview
Brief Summary
Celiac plexus neurolysis (CPN) has been performed for nearly 100 years to alleviate the abdominal pain associated with pancreatic malignancy and other conditions, and is usually undertaken at a late stage in the disease process, when analgesic options have been largely exhausted or have led to significant and often unacceptable side effects. Until recently, CPN was most commonly performed under radiographic guidance; however, in the last 10 years, CPN has been routinely performed under endoscopic ultrasound (EUS) guidance. Several case series have demonstrated the efficacy and safety of this technique when used to treat the pain associated with pancreatic malignancy and/or chronic pancreatitis. However, the efficacy of EUS-guided CPN in the treatment of pain related to non-pancreatic malignancies has yet to be described. The goal of this study is to assess the efficacy of EUS-guided CPN in the management of pain in patients with abdominal non-pancreatic malignancies. Our hypothesis is that EUS-guided CPN will provide adequate pain relief in these patients.
Investigators
Rajesh Keswani
Asssociate Professor
Northwestern University
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of an unresectable, non-pancreatic malignancy, including gastric, small intestinal, or proximal colonic malignancies, as well as malignancies of the liver and bile ducts (based on above celiac plexus innervations)
- •Pain directly related to the primary malignant process, as determined by the referring oncologist
- •Pain determined to be refractory to standard medical therapy, or when the medical therapy is ineffective due to certain limitations (such as severe constipation), as determined by the referring oncologist
- •Willingness to undergo EUS-guided CPN
- •Age \> 18 years
- •ECOG performance status of grades 0-3 \[7\]
- •The patient will need to sign informed consent prior to inclusion in this study
Exclusion Criteria
- •Unable or unwilling to undergo an EUS-guided CPN
- •Contraindication to anesthesia, as determine during the preoperative clearance process
- •Refractory coagulopathy (INR \> 1.5) or thrombocytopenia (platelet count \< 50,000), or aspirin and/or clopidogrel use within 7 days of procedure
- •Current pregnancy
- •Prior celiac plexus block/neurolysis
- •Allergy to local anesthetics
- •ECOG performance status of grade 4 or higher
Outcomes
Primary Outcomes
Difference between the mean pain score prior to and 1 month after the procedure, as determined by the Brief Pain Inventory (BPI)
Time Frame: 1 month
The BPI will be filled out just prior to and 1 month after the procedure to assess the difference in the mean pain score after the procedure
Secondary Outcomes
- Difference in the mean 'level of interference of pain with daily life' score, as determined by the Brief Pain Inventory (BPI). This score will be determined before and after the procedure, determined at the same intervals as mean pain scores.(2 months)
- Difference in mean pain scores before and at 1 day after the procedure, 7 days after the procedure, 14 days after the procedure, and at 2 months after the procedure, as determined by the Brief Pain Inventory (BPI).(2 months)
- Narcotic use over a 24-hour period will be documented each time the Brief Pain Inventory (BPI) is completed(2 months)